This syringe technology developed under its product name "ChaSyr," (pronounced chaser), allows for the sequential administration of two separate intravenous (IV) medications with a single syringe, replacing multiple
The new initiative will help restart dosing of medication for patients who participated in previous clinical studies of exon skipping drugs – a promising approach to the disease
On January 9, 2014, Avillion announced it had entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of BOSULIF.
ProStrakan has now purchased the entire share capital of Archimedes for a consideration of £230 million in cash. Archimedes is a fast growing European-based specialty pharmaceutical company providing
The trial was conducted in the United States under a Food and Drug Administration Investigational New Drug protocol. The prospective, randomized, double-blind, placebo controlled study in patients with
The current suite supports the processing of ADVATE [Antihemophilic Factor (Recombinant)], the market leading full-length recombinant factor VIII (rFVIII) worldwide for the treatment of patients with hemophilia A.
The product name change from Lomustine (CCNU) to Gleostine represents the company’s strategic initiative to re-launch and re-brand its product pipeline of matured and innovative drugs. The new
Previous studies had demonstrated that VeloThrax also possesses enhanced thermostability, enabling distribution without cold chain requirements. VeloThrax is the Company’s proprietary DNI (dominant negative inhibitor) anthrax rPA (recombinant
ORBACTIV is the first and only antibiotic approved by FDA to treat ABSSSIs with a single, once-only administration. Once fully infused over three hours, the ORBACTIV treatment regimen
The studies were conducted by Professor Paul Quax, Ph.D., and Yaël Nossent, Ph.D., of the Department of Surgery, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.